Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 24;16(6):1036-1044.
doi: 10.3390/idr16060083.

Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study-Preliminary Results

Ziv Rosman  1   2 , Yasmin Maor  2   3 , Iris Zohar  2   3 , Gingy Ronen Balmor  1   2 , Miri Schamroth Pravda  1   2 , Adam Lee Goldstein  4 , Milena Tocut  2   5 , Arie Soroksky  1   2
Affiliations

Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study-Preliminary Results

Ziv Rosman et al. Infect Dis Rep. .

Abstract

Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection that has a high mortality rate. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease secreted by the liver. Its binding to the low-density lipoprotein (LDL) receptor enhances its degradation, causing an increase in LDL levels in the blood. Objectives: Administering a PCSK9 inhibitor leading to an increase in lipid uptake by the liver may positively affect septic patients due to the increased removal of endotoxins. Methods: This preliminary study aimed to examine the safety of PCSK9 inhibitor use in septic and septic shock patients. We treated five septic patients in the intensive care unit with 300 mg of alirocumab following serious adverse events for 28 days. Results: Four of our patients did not experience any adverse events, and all of them survived. One patient died after discharge from the intensive care unit, and this death was presumably not related to the study drug. The patients rapidly recovered from the inflammatory stage of sepsis. Conclusions: Alirocumab appears safe in severe sepsis and septic shock patients. The outcome data are promising. Only a basic safety profile can be assessed based on this pilot study. Further study with a PCSK-9 inhibitor in septic or septic shock patients is required to further determine its benefit in ICU patients.

Keywords: PCSK9 inhibitor; alirocumab; sepsis; septic shock.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient recruitment.
Figure 2
Figure 2
Procalcitonin levels.
Figure 3
Figure 3
IL-6 levels. Patient V’s IL-6 samples were partially lost.
Figure 4
Figure 4
CRP levels.
Figure 5
Figure 5
WBC levels.
See this image and copyright information in PMC

References

    1. Singer M., Deutschman C.S. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287. - DOI - PMC - PubMed
    1. Sriskandan S., Cohen J. Gram-positive sepsis: Mechanisms and Differences from Gram-Negative Sepsis. Infect. Dis. Clin. North Am. 1999;13:397–412. doi: 10.1016/S0891-5520(05)70082-9. - DOI - PubMed
    1. Medzhitov R., Preston-Hurlburt P. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397. doi: 10.1038/41131. - DOI - PubMed
    1. Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis. Virulence. 2014;5:213–218. doi: 10.4161/viru.27024. - DOI - PMC - PubMed
    1. Branger J., Knapp S. Role of Toll-Like Receptor 4 in Gram-Positive and Gram-Negative Pneumonia in Mice. Infect. Immun. 2004;72:788–794. doi: 10.1128/IAI.72.2.788-794.2004. - DOI - PMC - PubMed

LinkOut - more resources